see treatment of manifestations	
hematopoietic stem cell transplantation (hsct)	
enzyme replacement therapy (ert)	
val804met+p	
see agents/circumstances to avoid	
see therapies under investigation	
other	C0205394//Other//MTH	C0220886//Other location of complaint//MTH	C1271040//Other health professional//MTH	C1521979//Other Route of Drug Administration//MTH	C1546380//Other - Event Reason//MTH	C1546725//Other Specimen Source Code//MTH	C1546836//Other - Special Program Code//MTH	C1546840//Other - Publicity Code//MTH	C1546902//Other - Diagnosis Classification//MTH	C1546930//Other - Report Source//MTH	C1547110//Other - Modality//MTH	C1547196//Other - Organization unit type//MTH	C1547233//Other - Triage Code//MTH	C1547241//Other - Newborn Code//MTH	C1547267//Other - Risk Management Incident Code//MTH	C1547272//Other - Incident Type Code//MTH	C1547281//Other - Production Class Code//MTH	C1547292//Other - Recreational Drug Use Code//MTH	C1547304//Other - Precaution Code//MTH	C1547309//Other - Patient Condition Code//MTH	C1547994//Other - Diagnostic Service Section ID//MTH	C1549063//Other - Notify Clergy Code//MTH	C1549104//Other - Administrative Gender//MTH	C1549110//Other - Marital Status//MTH	C1550146//Other - Substance Type//MTH	C1556042//Other - Relationship//MTH	C1556043//Other - Religion//MTH	C1556044//other - No Information//MTH	C1556045//Other - What subject filter//MTH	C1556046//Other - Employment Status//MTH	C1556048//Other - Contact Role//MTH	C1556049//Other - Mail Claim Party//MTH	C1556050//Other - Living Dependency//MTH	C1556051//Other - Event Consequence//MTH	C1556052//Other - Indirect exposure mechanism//MTH	C1556053//Other - Action Taken in Response to the Event//MTH	C1556054//Other - Status of Evaluation//MTH	C1556055//Other - Causality Observations//MTH	C1556056//Other - Job Status//MTH	C1556057//Other - Immunization Registry Status//MTH	C1561608//Other - Mode of Arrival//MTH	C1868670//Other Growth//MTH	C1996846//Other (qualifier in LNC)//MTH	C2598149//Other:-:Point in time:^Patient:-//MTH	C3496095//Other - HRSA Program//MTH	C3889261//Other License Status//MTH	C4050255//Other Establishment Activity//MTH
none	C0456148//Null Value//MTH	C0549184//None//MTH	C1546509//none - TableRules//MTH	C1547191//none - ResponseLevel//MTH	C1550083//None - Specimen Additive//MTH	C1550437//None - Sequencing//MTH	C1551387//None - ContainerSeparator//MTH	C1553523//none - SubstanceAdminSubstitution//MTH	C1556146//None - Relationship//MTH	C1556147//None - Eligibility Source//MTH	C1556148//None - Action Taken in Response to the Event//MTH	C1556150//None - ObservationValue//MTH	C1556151//None - Language Proficiency//MTH	C1556152//None - Additive/Preservative//MTH	C1706277//None Device Component//MTH	C4050154//No Hand Mobility//MTH	C4050155//No Support Needed//MTH
8 yrs	
dietary management	C0012159//Diet therapy//MTH	C0012160//nutritional management//MTH
antioxidants	C0003402//Antioxidants//MTH
prevention of secondary manifestations	
appropriate measures include the following:	
breast cancer	C0006142//Malignant neoplasm of breast//MTH	C0678222//Breast Carcinoma//MTH
bone marrow transplantation (bmt)	
prevention of acute attacks	
liver transplantation	C0023911//Transplantation of liver//MTH
dietary guidelines for hereditary fructose intolerance (hfi)	
adapted from www	
edu/aldolase/hfi/treatment/sugar_table	
htm	
risk for aggressive mtc based on genotype and recommended interventions	
20 yrs	
ata = american thyroid association	
ser649leu and p	
hpt = hyperparathyroidism	
pathogenic variants in cis configuration on one allele	
criteria: normal annual basal and or stimulated serum calcitonin	
normal annual neck ultrasound examination	
family history of less aggressive mtc	
organ transplantation	C0029216//Organ Transplantation//MTH
pathophysiology	C0031847//physiopathological//MTH	C0277785//Functional disorder//MTH
low-fat diet	C0242970//Fat-Restricted Diet//MTH
no formal guidelines for amount of dietary fat exist	
multiple small meals	
no evidence-based guidelines exist	
good hydration	
gene therapy	C0017296//gene therapy//MTH
antibiotic prophylaxis	C0282638//Antibiotic Prophylaxis//MTH
most affected individuals are clinically normal at birth	
hb bart syndrome	
no specific treatment is available for the sensorimotor neuropathy	
lifestyle and dietary modification to avoid known triggers	
bmt/sct from a “non-ideal” donor	
ert is not curative	
more than 300 affected individuals have received peg-ada	
in individuals who lack an hla-identical donor)	
chan et al 2005	
kaufman et al 2005	
husain et al 2007	
author, unpublished data]	
a third affected individual died of hepatoblastoma after 2	
5 years of ert	
these are of no clinical significance	
seek timely treatment of systemic illness or infection	
avoid excessive alcohol consumption and smoking	
regular weight-bearing exercises are encouraged to maintain bone health	
restriction of dietary protein through use of specialized formulas	
administration of oral nitrogen scavenging drugs	
9-13	
0 g/m2/day in larger patients	
diet	C0012155//Diet//MTH	C0012159//Diet therapy//MTH	C1519433//Special Diet Therapy//MTH	C1549512//diet - supply//MTH	C2983588//Basal Diet//MTH	C3668949//Diet (animal life circumstance)//MTH
arginine base supplementation	
8-15	
oral nitrogen scavenging therapy	
orthotopic liver transplantation (olt)	
management relies on personalized recommendations based on clinical assessment	
implantable cardioverter-defibrillators (icds)	
syncope was found to predict appropriate icd discharge	
class ii indications (i	
uveal melanoma	C0220633//Uveal melanoma//MSH
malignant mesothelioma	C0345967//Malignant mesothelioma//MTH
cutaneous melanoma	C0025202//melanoma//MTH	C0151779//Cutaneous Melanoma//MTH
complete sunblock should be used	
avoidance of triggers/stressors including trauma and surgery	
no preventive or curative treatment is available for bhds	
biotin therapy is lifelong	
a protein-restricted diet is not necessary	
branchial arch anomalies can be surgically corrected	
consider prophylactic bilateral mastectomy	
chemoprevention	C0278925//chemoprevention of cancer//MTH	C0282515//Chemoprevention//MTH
the sample size, however, was extremely small	
ovarian cancer/fallopian tube cancer	
salpingectomy	C0041271//Salpingectomy//MTH
tubal ligation	C0520483//Tubal Ligation//MTH
there are no preventive measures for stroke or vascular dementia	
salt-wasting crisis	
flu prevention (i	
a later age of onset of symptoms	
strict avoidance of sunlight and protection from light are indicated	
antibacterial prophylaxis	C0877426//Antibacterial prophylaxis//MDR
antifungal prophylaxis	C0877136//Antifungal prophylaxis//MDR
immunomodulatory therapy	C1963758//Immunomodulation//MTH
9 months	
13 to 0	
4 per patient year	
the data for this are anecdotal and unimpressive	
for bsa >0	
for bsa ≤0	
5/m2 the dose is 1	
5 μg/kg subcutaneously 3x/week	
allogeneic hsct is the only known cure for cgd	
, aspergillosis)	
high-carbohydrate meals and alcohol should be avoided	
arginine administration may be effective in preventing hyperammonemic crises	
aro	C0019952//Anesthesia-Resuscitation Department, Hospital//MSH	C1366496//CYP19A1 gene//MTH	C1705771//CYP19A1 wt Allele//MTH
a schulz and u kornak, unpublished results]	
schulz and moshous, personal communication]	
these individuals should receive prophylactic anticholinesterase therapy	
no treatment reverses or slows the natural progression of cmt	
infusions of glucose during intercurrent infections to prevent catabolism	
note: oral glucose cannot achieve this effect	
frequent meals and avoidance of extended fasting	
avoidance of prolonged exercise and other known triggers	
3 to 1	
95 g/m2/day)	
procysbi® is taken every 12 hours	
cysteamine increases gastrin synthesis and gastric acid production	
55% solution with benzalkonium chloride 0	
recommended drugs are nadolol (1-2	
granulocyte colony-stimulating factor (g-csf)	
dale, unpublished observations]	
, 5-10 µg/kg/day)	
for individuals with ts-nsan:	
prevent febrile episodes	
physical therapy may prevent early joint contractures	
as such, empiric recommendations include the following:	
supplement with levocarnitine if deficient	
avoid liver-toxic medications	
acetazolamide could stabilize channels that fail to properly inactivate	
use of soft and properly fitted clothing and footwear	
however, there is no limitation	
note: when indicated, splenectomy is curative	
2 mg/kg every 2 weeks)	
06) [banikazemi et al 2007]	
the largest comparative study is the canadian fabry disease initiative	
3 g/kg every other week	
and compliance should be closely monitored	
prophylactic anticoagulation	
pregnancy	C0032961//Pregnancy//MTH
prophylactic anticoagulation during pregnancy:	
pharmacologic and surgical interventions have focused on palliation of symptoms	
weighted gloves can sometimes be used to assist with dysmetria	
ablative pallidotomy or thalamotomy	
colchicine	C0009262//Colchicine//MSH
homozygotes/compound heterozygotes	
individuals who are homozygous for the pathogenic variant p	
met694val or compound heterozygous for p	
children may need 0	
5-1 mg/day according to age and weight	
affected individuals should receive colchicine for life	
individuals who do not have the p	
glu148gln	
heterozygotes	C0019425//Heterozygote//MSH
treatment of affected individuals who are unresponsive to colchicine	
some individuals appear to be unresponsive to colchicine treatment	
weekly intravenous colchicine (1	
this is not a long-term solution	
the possibility of interferon alpha side effects (e	
, chills and fatigue) should also be considered	
sulphasalazine	C0036078//Sulfasalazine//MSH
she was homozygous for the pathogenic variant p	
dietary intervention	C0086153//Dietary Modification//MSH
, isomil® or prosobee®)	
furthermore, such tests may not be available	
, combined ert and bmt)	
it is likely that end-stage histologic changes (e	
ert is well tolerated	
adverse effects (e	
, brain, bones, and lungs)	
substrate reduction therapy (srt)	
6 to -0	
crim status	
age restrictions on lumizyme were removed in 2014	
many individuals are now treated with the higher dose	
complications of ert	
infusion-associated reactions	
prognosis	C0033325//Forecast of outcome//MTH	C3854082//Prognosis:Find:Pt:^Patient:Nom//MTH
iopd	
lopd	
the major morbidities are motor disability and respiratory insufficiency	
see treatment of manifestations and agents/circumstances to avoid	
liver phk deficiency	
hypoglycemia	C0020615//Hypoglycemia//MTH
6 to 2	
some individuals may require cornstarch only before bedtime	
requirements for cornstarch tend to lessen with age	
muscle phk deficiency	
however, regular moderate aerobic exercise may be beneficial	
involves the following:	
selection of appropriate contraception for females	
a copper-eluting iud is theoretically the safest in porphyria	
however, little information exists	
suppression of menses using a gnrh agonist	
, propofol, ketamine, short-acting benzodiazepines)	
does not	C1299585//Does not//SNOMEDCT_US
involve the following:	
use of glucose	
extreme diets (e	
no known treatment stops or slows the progression of hdl2	
5 to three years	
the following measures are recommended:	
avoidance of drugs and agents that induce the hepatic p450	
vaccination against hepatitis a and b	
table 3	
food category	
foods permitted	
foods prohibited	
dairy	C3687582//Produces milk for human food//SNOMEDCT_VET
any milk, cheese, eggs	
meat	C0025017//Meat//MTH	C1561493//Animal raised for meat production//MTH	C2347088//Meat Flavor//MTH
beef, veal, lamb, pork	
ham, bacon, hot dogs, processed meats	
any other meat where sugar is used in processing	
fish	C0016163//Fishes//MTH	C0162789//Fluorescent in Situ Hybridization//MTH	C0452961//fish - non-drug agent//MTH	C1822711//SH3PXD2A gene//MTH	C2700184//Fish Flavor//MTH	C3257082//Fish extract//MTH	C3274826//SH3PXD2A wt Allele//MTH
all fish	
poultry	C0032850//Fowls, Domestic//MTH	C0452888//Poultry Meat//MTH
chicken, turkey	
cereal	C0007757//Cereals//MTH
sweetened/sugar-coated cereals	
fruit	C0016767//Fruit//MTH	C1509510//Fruit Flavor//MTH
vegetables	C0042440//Vegetables//MTH
all other vegetables, including sweet potatoes	
bread	C0006138//Bread//MSH
soda crackers & saltines	
any breads or crackers prepared w/fructose/sucrose/sugar/sorbitol	
fat sources	
desserts and sweeteners	
dietetic jello, dietetic ice cream, dietetic puddings	
natural yogurt	
sugar, sucrose, sorbitol, fructose	
miscellaneous	C0205395//Miscellaneous//MTH	C1706184//Miscellaneous Potency Unit//MTH
some sugar substitutes	
some dietetic beverages	
pasta	C0452694//Pasta//SNOMEDCT_US
rice	C0035567//Rice (Dietary)//MTH	C1140671//Oryza sativa//MTH	C1509547//Rice Preparation//MTH	C3484401//brown rice preparation//MTH
cinnamon, garlic, poppy seeds	
peanut butter if prepared w/added sugars	
chewing gum w/sorbitol	
the following are recommendations:	
biopsy-proven diffuse-type gastric carcinoma	
heterozygotes for a germline cdh1 pathogenic variant	
however, the morbidity from prophylactic gastrectomy is high	
the age-specific risks of gastric cancer	
citrulline supplementation at 0	
17 g/kg/day or 3	
lysine supplementation is indicated when plasma lysine concentrations are low	
liver transplantation is not indicated for persons with hhh syndrome	
betaine therapy is usually added to the therapeutic regimen	
details about each aspect of treatment follow	
vitamin b6 (pyridoxine) therapy	
dietary treatment	
this diet should be continued indefinitely	
folate and vitamin b12 supplementation	
betaine treatment	
side effects of betaine are few	
acetazolamide treatment:	
is beneficial in approximately 50% of individuals with hokpp	
has no effect in 30% of affected individuals	
alternatives to acetazolamide	
pinacidil [ligtenberg et al 1996]	
and bumetanide [wu et al 2013]	
5 mg/kg	
more recently, in a 3	
long-term use of ert was safe	
and	C0002838//Andorra//MTH	C1515981//And//MTH	C1550557//RelationshipConjunction - and//MTH	C1706368//And - dosing instruction fragment//MTH
, infliximab)	
itching	C0033774//Pruritus//MTH	C3641891//Have Itch//MTH	C4084921//Usual Severity Itching//MTH	C4085219//How Much Distress Itching//MTH	C4085640//How Often Itching//MTH
rash	C0015230//Exanthema//MTH
flushing	C0016382//Flushing//MTH	C1962957//Flushing Adverse Event//MTH
and headache	
treatment of hyperuricemia with allopurinol can prevent development of gout	
diet/environment	
potassium-rich medications and foods (e	
, fruits, fruit juices)	
fasting	C0015663//Fasting//MTH
strenuous work	
exposure to cold	C0231275//Cold exposure//SNOMEDCT_US
diuretics	C0012798//Diuretics//MSH
preventive measures include the following:	
statin-based therapy with addition of other medications as needed	
reduced intake of saturated fat	
increased intake of soluble fiber to 10-20 g/day	
increased physical activity	C4039165//Increased physical activity//SNOMEDCT_US
not smoking	
see treatment of manifestations, clonazepam	
bmt is currently the only cure for ipex syndrome	
treatment by phlebotomy in presymptomatic stages can prevent organ damage	
treated individuals show improved and preserved cognitive function	
thiamine transporter deficiency (mutation of slc19a3)	
biotinidase deficiency (btd)	
coenzyme q10 biosynthesis defect (pdss2)	
, prolonged lethargy, depression)	
up to ten hours during the second year of life	
up to 12 hours after age two years	
to avoid excessive fasting:	
infants require frequent feedings	
a relatively low-fat diet (e	
kidney transplantation cures adtkd-umod	
the transplanted kidney does not develop the disease	
no specific treatment for melas exists	
prophylactic thyroidectomy is safe for all age groups	
table 4	
ata 1 risk level	
pathogenic variants 2, 3	
age of prophylactic surgery	
age to begin screening	
for pheo	
for hpt 4	
level d(highest risk)	
ala883phep	
met918thrp	
glu805lys 5p	
tyr806cys 5p	
ser904cys 5	
as soon as possible in 1st year of life	
level c	
cys634arg/gly/phe/ser/trp/tyr	
<5 yrs	
level b	
cys609phe/arg/gly/ser/tyrp	
cys611arg/gly/phe/ser/trp/tyrp	
cys618arg/gly/phe/ser/tyrp	
cys620arg/gly/phe/ser/trp/tyrp	
cys630arg/phe/ser/tyrp	
asp631tyrp	
633/9 bp dupp	
634/12 bp dupp	
val778ile 5	
consider <5 yrs	
may delay if criteria met 5	
level a	
arg321glyp	
531/9 bp dupp	
532 dupp	
cys515serp	
gly533cysp	
arg600glnp	
lys603glup	
tyr606cysp	
635/insert elcr	
thr636prop	
lys666glup	
glu768aspp	
asn777serp	
leu790phep	
val804leu/metp	
gly819lysp	
arg833cysp	
arg844glnp	
arg866trpp	
ser891alap	
arg912pro	
may delay beyond age 5 yrs if criteria met 6	
six months for children with men 2b	
menkes disease	C0022716//Menkes Kinky Hair Syndrome//MTH
occipital horn syndrome	C0268353//Cutis laxa, x-linked//MTH
medicalert	
org)	
they reflect evolving pretreatment conditioning and improved donor matching	
hsct failures continue	
nevertheless, some improvement has been seen	
nutrition	C0028707//Science of nutrition//MTH	C0392209//Nutritional status//MTH	C0518896//Nutrition outcomes//MTH	C0600072//Feeding and dietary regimes//MTH	C1442959//Nutrition function//MTH	C1521729//Nutritional Study//MTH
after stabilization, nutritional management is critical	
a propiogenic amino acid-deficient formula (e	
isolated valine or isoleucine supplementation should be avoided	
hydroxocobalamin injections	
antibiotics	C0003232//Antibiotics//MTH	C0003237//Antibiotics, Antitubercular//MTH	C3540704//Antibiotics for systemic use//MTH	C3540705//Antifungal Antibiotics, Topical//MTH	C3540706//Antibiotic throat preparations//MTH	C3540707//Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE//MTH	C3540708//Antibiotics, Gynecological//MTH	C3540709//antibiotics, intestinal//MTH	C3540710//Antibiotics, ophthalmologic//MTH
rotating antibiotic regimens may be considered in some persons	
kidney transplantation	C0022671//Kidney Transplantation//MTH
a second patient developed progressive neurologic symptoms	
and two others developed metabolic decompensations post transplant	
adults have not undergone hsct	
all published reports indicate that ert is well tolerated	
hepatic volume normalized in 92%	
respiratory function either improved slightly or remained constant	
timed walk measurements remained largely constant	
growth resumed in approximately 70%	
the most common reactions were of an immune nature	
other studies have shown:	
5-4	
see treatment of manifestations for information regarding ert	
normal weight gain, linear growth, and head growth	
home formula supplies include bcaa-free powder	
normal age- and weight-adjusted energy intake	
appropriate leucine tolerance	
goals of laboratory monitoring:	
plasma isoleucine concentration approximately equal to plasma leucine concentration	
plasma valine concentration at least twofold plasma leucine concentration	
thiamine treatment	
9-20	
mt-rnr1-related aminoglycoside-induced ototoxicity	
thrombocytopenia cannot be prevented	
oral contraceptives are often effective in preventing or controlling menorrhagia	
exercise temporarily alleviates myotonia (the warm-up effect)	
the effect has not been systematically studied	
treatment and monitoring may then start immediately	
variable results have been reported with hsct	
enzyme replacement therapy	C0598391//Enzyme Replacement Therapy//MSH
skin that burns with sun exposure needs protection	
an early (pediatric) dermatologic consultation is warranted	
all primary manifestations are present at birth	
however, small meals may minimize pancreatic exocrine stimulation	
circumstances to avoid	
dehydration worsens episodes of acute pancreatitis	
no curative therapy is presently available for pbd, zss	
consistent, regular care of the conditions is necessary	
minimize intercurrent infections as environmental stressors	
5 mg for infants and 2 mg for adults	
studies have indicated that higher doses may enhance intellectual development	
such therapy is required for life	
always maintain good hydration	
avoid activities that potentially increase blood viscosity (e	
, mountain climbing, scuba diving, smoking)	
severe atp8b1 deficiency	
mild atp8b1 deficiency	
vaccination against hepatitis a and b is appropriate	
acute attack	
weekly or biweekly hemin infusions may prevent frequent noncyclical attacks	
however, published experience is lacking	
photocutaneous	
pre-prandial plasma essential amino acids	
plasma albumin	C0857876//Plasma Albumin Test//MTH	C1260311//Plasma Albumin//MTH
prealbumin	C0032923//Prealbumin//MTH	C0337441//Prealbumin measurement//MTH
hemoglobin	C0019046//Hemoglobin//MTH	C0518015//Hemoglobin measurement//MTH	C1561562//Hemoglobin finding//MTH	C2239101//Hemoglobin Adverse Event//MTH
plasma ammonia	C4481708//plasma ammonia//MEDCIN
plasma vitamin d	
essential fatty acid profile	
additional calories can be provided using protein-free formulas	
medications	C0013227//Pharmaceutical Preparations//MTH	C0802604//Medications:Presence or Identity:Duration of the study:^Patient:Nominal//MTH	C2598133//Medications:-:Point in time:^Patient:-//MTH	C4284232//Medications//MTH
levocarnitine	C0087163//Levocarnitine//MTH
the optimal dose of levocarnitine has not been established	
levocarnitine can be given enterally and intravenously	
antimicrobial therapy	
biotin supplementation	
management during episodes of metabolic decompensation includes:	
avoidance of fasting (e	
, using intravenous dextrose)	
increasing calorie intake to prevent catabolism (e	
, intravenous fat emulsion)	
olt in patients with pa is not curative	
sedation and perioperative management	
emergency situations	C0013956//Emergency Situation//MTH
prevention of primary manifestations in hereditary pancreatitis is limited	
no curative therapy currently exists for refsum disease	
see treatment of manifestations, pharmacologic treatment	
beta blockers	C0001645//Adrenergic beta-Antagonists//MTH
icd	C0020725//Type II Mucolipidosis//MTH	C0021122//Disruptive, Impulse Control, and Conduct Disorders//MTH	C0162589//Implantable defibrillator//MTH	C0870733//International Classification of Diseases//MTH	C1550747//between lunch and dinner//MTH
ongoing education is essential to help minimize morbidity and mortality	
maintaining hydration and avoiding extremes of climate	
monitoring for signs and symptoms requiring acute medical intervention	
early detection of chronic complications	
updates on new therapies	
chronic red blood cell transfusion therapy	
prevention of stroke recurrence	
treatment of chronic pain refractory to other therapies	
pulmonary hypertension	C0020542//Pulmonary Hypertension//MTH	C1963220//Pulmonary Hypertension Adverse Event//MTH
chronic renal failure	C0022661//Kidney Failure, Chronic//MTH	C1561643//Chronic Kidney Diseases//MTH	C2316810//Chronic kidney disease stage 5//MTH
recurrent episodes of acs	
severe end-organ damage	
metabolism into nitric oxide, a potent vasodilator	
overall improvement in blood flow	
reduction of vascular inflammation	
hydroxyurea can have potentially significant toxicity, including myelosuppression	
gov/ct2/show/nct01179217)	
orthotopic liver transplantation (oltx)	
age younger than 60 years	
disease duration less than five years	
no significant cardiac or renal dysfunction	
fapwtr	
org/ram_fap	
severe polyneuropathy (norris score <55/81)	
permanent urinary incontinence	
marked postural hypotension	
a fixed pulse rate	
[behrend et al 2012]	
however, the efficacy remains controversial	
severe exercise (e	
infection	C0009450//Communicable Diseases//MTH	C1556682//Adverse Event Associated with Infection//MTH	C3714514//Infection//MTH
intravenous immune globulin	C0085297//Immunoglobulins, Intravenous//MTH
routine childhood immunizations	
live vaccines should be avoided	
bleeding	C0019080//Hemorrhage//MTH
splenectomy	C0037995//Splenectomy//MSH
platelet transfusions	C0086818//Platelet Transfusion//MSH
platelet transfusions should be administered judiciously (e	
, for significant bleeding and surgical procedures)	
hla-matched bone marrow transplantation from a relative is preferred	
cord blood from normal infants is now being banked	
bmt after age 3	
administration of immunoglobulin	
see also therapies under investigation	
bacterial infections	C0004623//Bacterial Infections//MTH
both routes provide good therapeutic concentrations of serum igg	
a variety of brands of gammaglobulin are available	
such reactions may disappear over time	
the following methods are used to prevent infection:	
intravenous immune globulin (ivig)	
outcomes are the best with hla-matched, related donors	
matched unrelated donor	C4318937//Matched Unrelated Donor//MTH
umbilical cord blood donor	
all individuals were alive at a median of 13	
5 years of follow up	
two individuals receiving myeloablative conditioning have developed premature ovarian failure	
